A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Haense, N ^a   Atmaca, A ^a   Pauligk, C ^a   Steinmetz, K ^a   Marme F ^b   Haag, G M ^b   Rieger, M ^c   Ottmann, O G ^d   Ruf, P ^e   Lindhofer, H ^e   Al Batran, S E ^a  

^a KRANKENHAUS NORDWEST   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c Onkologische Schwerpunktpraxis   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e TRION Research GmbH   (Germany)

Author keywords

Advanced cancer; Dose escalation; Dose limiting toxicity; Ertumaxomab; Her2 neu; Maximum tolerated dose

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERTUMAXOMAB; GAMMA GLUTAMYLTRANSFERASE; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ARTICLE; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEAD AND NECK CANCER; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; HYPOTENSION; LIMB PAIN; LYMPHOCYTE; MALE; MIDDLE AGED; NAUSEA; PAIN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; RECTUM CANCER; SENSORY SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH CANCER; TACHYCARDIA; TREATMENT FAILURE; VOMITING; BREAST NEOPLASMS; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; METABOLISM; RECTAL NEOPLASMS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RECEPTOR, ERBB-2; RECTAL NEOPLASMS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84978419925     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2449-0     Document Type: Article

References (20)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82.
2. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998;16(6):413-28.
3. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986;232(4758):1644-6.
4. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 1997;410(1):83-6.
5. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 2001;8(1):11-31.
6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92.
7. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol. 1999;163(3):1246-52.
8. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol. 1995;155(1):219-25.
9. Zeidler R, Mysliwietz J, Csánady M, Walz A, Ziegler I, Schmitt B, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000;83(2):261-6.
10. Kontermann R, editor. Bispecific Antibodies. Berlin: Springer-Verlag; 2011.
11. Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem. 2001;49(7):911-7.
12. Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marmé A, et al. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res. 2006;12(10):3085-91.
13. Eissler N, Ruf P, Mysliwietz J, Lindhofer H, Mocikat R. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res. 2012;72(16):3958-66.
14. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001;98(8):2526-34.
15. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209-21.
16. Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res. 2009;69(10):4270-6.
17. Dettmar K, Seitz-Merwald I, Lindemann C, Schroeder P, Seimetz D, Atz J. Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo. Clin Transl Oncol. 2012;14(5):376-81.
18. Ott MG, Marmé F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, Essing MM, Linke R, Seimetz D. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer. 2012;130(9):2195-203.
19. Atanackovic D, Reinhard H, Meyer S, Spöck S, Grob T, Luetkens T, Yousef S, Cao Y, Hildebrandt Y, Templin J, Bartels K, Lajmi N, Stoiber H, Kröger N, Atz J, Seimetz D, Izbicki JR, Bokemeyer C. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Hum Vaccin Immunother. 2013;9(12):2533-42.
20. Ladjemi MZ, Jacot W, Chardès T, Pèlegrin A, Navarro-Teulon I. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother. 2010;59(9):1295-312.